Table 4.
Pharmacology Summary: Reference Compound Potencies
| Cav1.2 | Cav2.1 | Cav2.2 | Cav3.2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference compound | Pre-pulse −50 mV | Pre-pulse −90 mV | 0.1 Hz | Pre-pulse −50 mV | Pre-pulse −90 mV | 0.1 Hz | Pre-pulse −50 mV | Pre-pulse −90 mV | 0.1 Hz | Pre-pulse −75 mV | Pre-pulse −90 mV | 1 Hz |
| Verapamil | 6.5±1.5 | 25.3±5.2 | 5.3±1.1 | 5.0±1.1 | 22.1±4.7 | 12.4±3.6 | 13.1±2.7 | 46.0±8.7 | 17.8±3.1 | 14.3±3.3 | 21.2±3.8 | 12.7±1.8 |
| Nifedipine | 0.023±0.007 | 0.085±0.026 | 0.10±0.013 | >3.0 | >3.0 | >3.0 | >3.0 | >3.0 | >3.0 | >3.0 | >3.0 | >3.0 |
| BAY K8644 | (0.006; 0.005)a | ND | ND | 5.4±0.9 | 24.8±7.3 | 10.0±2.6 | (13.6, 14.3) | (54.7, 37.2) | (17.3, 16.1) | 10.8±1.9 | 11.5±0.6 | 7.2±0.7 |
| Pimozide | >30.0 | 27.8±9.8 | 1.9±0.6 | >30.0 | >30.0 | >30.0 | >30.0 | >30.0 | >30.0 | 8.9±3.6 | 7.2±1.2 | 5.5±1.3 |
| Mibefradil | 10.8±3.10 | 16.1±4.6 | 8.0±1.8 | 6.5±1.2 | 4.0±1.1 | 2.2±0.6 | 10.8±1.3 | 8.4±2.1 | 3.0±0.2 | 3.30±0.9 | 3.7±1.0 | 2.0±0.9 |
Data are mean±SD IC50s (in μM) from three to four experiments; where only two experiments were run, data from each experiment are listed.
a
EC50, BAY K8644 potentiated Cav1.2.
ND, not determined.